January 2018

Home  /  2018  /  January

This is the assessment of the relative effectiveness of “Alectinib (Alecensa©) as monotherapy for the first line treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC)". This is a revised version of the report originally posted on January

Final Assessment Report, External Comments/Answers and Project Plan for Other Technologies CA MammaPrint® This is the assessment of the relative effectiveness of MammaPrint® - Added value of using the gene expression signature test MammaPrint® for adjuvant chemotherapy decision-making in early breast